Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160257 | 0.91 | MMP1 (0.41) | TRPV4OPRM1OPRK1OPRD1SLC22A12 | |
| SCHEMBL14427270 | 0.88 | MMP1 (0.43) | TRPV4OPRM1OPRK1OPRD1SLC22A12 | |
| SCHEMBL5435868 | 0.87 | MMP8 (0.44) | OPRM1OPRK1OPRD1MMP1HRH3 | |
| SCHEMBL14427268 | 0.85 | MMP1 (0.54) | TRPV4SLC22A12MMP1 | |
| SCHEMBL5441474 | 0.84 | MMP1 (0.41) | OPRM1OPRK1OPRD1MMP1USP2 | |
| SCHEMBL5441239 | 0.84 | MMP1 (0.41) | OPRM1OPRK1OPRD1MMP1USP2 | |
| SCHEMBL5440459 | 0.84 | MMP1 (0.41) | OPRM1OPRK1OPRD1MMP1USP2 | |
| SCHEMBL5435725 | 0.83 | TAS2R14 (0.43) | OPRM1OPRK1OPRD1MMP1USP2 | |
| SCHEMBL5430840 | 0.83 | MMP8 (0.42) | OPRM1OPRK1OPRD1MMP1HRH3 | |
| SCHEMBL5437373 | 0.83 | MMP8 (0.42) | OPRM1OPRK1OPRD1MMP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-30 | — | — | US | claimed |
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203118-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | MMP9, MMP2, MMP3 | TRPV4 1913/4885OPRM1 1548/4885OPRK1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.